• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Synergy CHC Corp.

    4/13/26 5:03:31 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care
    Get the next $SNYR alert in real time by email
    S-8 1 ea0285991-s8_synergy.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on April 13, 2026

    Registration No. 333-       

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    SYNERGY CHC CORP.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Nevada   99-0379440

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification Number)

         

    770 Roosevelt Trail STE 8 #1016

    N. Windham, Maine

     

    04062

    (Address of Principal Executive Offices)   (Zip Code)

     

    Synergy CHC Corp. 2024 Equity Incentive Plan

    (Full Title of the Plan)

     

    Jack Ross

    Chief Executive Officer

    c/o Synergy CHC Corp.

    770 Roosevelt Trail STE 8 #1016

    N. Windham, Maine 04062

    (Name and Address of Agent for Service)

     

    (207) 321-2350

    (Telephone Number, Including Area Code, of Agent for Service)

     

    Copies to:

     

    W. David Mannheim

    Michael K. Bradshaw, Jr.

    Nelson Mullins Riley & Scarborough LLP

    301 Hillsborough Street, Suite 1400

    Raleigh, North Carolina 27603

    (919) 329-3800

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The documents containing information specified by Part I of this Registration Statement on Form S-8 (this “Registration Statement”) have been or will be sent or given to participants in the plan listed on the cover of this Registration Statement (the “Plan”) as specified in Rule 428(b)(1) promulgated by the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”). Such documents are not being filed with the SEC but constitute (along with the documents incorporated by reference into the Registration Statement pursuant to Item 3 of Part II hereof) a prospectus which meets the requirements of Section 10(a) of the Securities Act.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed with the Commission are incorporated herein by reference:

     

      ● The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on April 1, 2026;

     

      ● The Registrant’s Current Reports on Form 8-K filed with the SEC on March 3, 2026 and March 25, 2026; and

     

      ● The description of the Registrant’s common stock contained in its Registration Statement on Form 8-A, as filed with the SEC on October 21, 2024, including any amendments or reports filed with the SEC for the purpose of updating such description.

     

    All documents subsequently filed with the SEC by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, prior to the filing of a post-effective amendment to this registration statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement (in each case excluding any information furnished and not filed according to applicable rules, such as information furnished pursuant to Item 2.02 or Item 7.01 on any Current Report on Form 8-K) and to be part hereof from the date of filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference in this registration statement shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained in this registration statement, or in any other subsequently filed document that also is or is deemed to be incorporated by reference in this registration statement, modifies or supersedes such prior statement. Any statement contained in this registration statement shall be deemed to be modified or superseded to the extent that a statement contained in a subsequently filed document that is or is deemed to be incorporated by reference in this registration statement modifies or supersedes such prior statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Item 4.  Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    None.

     

    II-1

     

     

    Item 6. Indemnification of Directors and Officers.

     

    Neither our articles of incorporation, nor our amended and restated bylaws, prevent us from indemnifying our officers, directors and agents to the extent permitted under the Nevada Revised Statutes (“NRS”). NRS Section 78.7502 provides that a corporation may indemnify any director, officer, employee or agent of a corporation against expenses, including attorneys’ fees, actually and reasonably incurred by him in connection with any defense to the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 78.7502(1) or 78.7502(2), or in defense of any claim, issue or matter therein.

     

    NRS 78.7502(1) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.

     

    NRS Section 78.7502(2) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys’ fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

     

    NRS Section 78.747 provides that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether a director or officer acts as the alter ego of a corporation.

     

    Our amended and restated bylaws provide that we will indemnify our directors, officers, employees and agents to the extent and in the manner permitted by the provisions of the NRS, as amended from time to time, subject to any permissible expansion or limitation of such indemnification, as may be set forth in any stockholders’ or directors’ resolution or by contract. Any repeal or modification of these provisions approved by our stockholders will be prospective only and will not adversely affect any limitation on the liability of any of our directors or officers existing as of the time of such repeal or modification. We are also permitted to apply for insurance on behalf of any director, officer, employee or other agent for liability arising out of his actions, whether or not the NRS would permit indemnification.

     

    We have entered into indemnification agreements with each of our officers and directors.

     

    These agreements require us to indemnify these individuals to the fullest extent permitted under Nevada law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.

     

    II-2

     

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    The following exhibits are filed as part of this Registration Statement:

     

    Exhibit No.   Description
    4.1   Articles of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on September 16, 2024).
       
    4.2   Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. on June 18, 2025).
         
    4.3   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on June 28, 2024).
       
    5.1*  

    Opinion of Nelson Mullins Riley & Scarborough LLP as to the legality of the securities being registered.

         
    23.1*   Consent of RBSM LLP, Independent Registered Public Accounting Firm.
       
    23.2*   Consent of Nelson Mullins Riley & Scarborough LLP (included as part of Exhibit 5.1).
       
    24.1*   Power of Attorney (included on signature page).
         
    99.1   Synergy CHC Corp. 2024 Equity Incentive Plan and Amendment No. 1 thereto (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on July 29, 2024).
         
    99.2   Amendment No. 2 to Synergy CHC Corp. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed by Synergy CHC Corp. on June 18, 2025).
         
    107*   Filing Fee Table

     

    * Filed herewith.

     

    II-3

     

     

    Item 9. Undertakings.

     

    (a)The Registrant hereby undertakes:

     

    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Table” table in the effective Registration Statement.

     

    (iii)To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)To remove from registration by means of post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b)The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of N. Windham, State of Maine, on April 13, 2026.

     

      SYNERGY CHC CORP.
         
      By: /s/ Jack Ross
        Jack Ross
        Chief Executive Officer and Chairman

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of Synergy CHC Corp., hereby, severally constitute and appoint each of Jack Ross and Jaime Fickett as our true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, in any and all capacities, to sign this Registration Statement on Form S-8 and any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as she/he might or could do in person, hereby ratifying and confirming all that such attorney-in-fact and agent, or her/his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Dates
           
    /s/ Jack Ross   Chief Executive Officer and Chairman
    (Principal Executive Officer)
      April 13, 2026
    Jack Ross    
           
    /s/ Jaime Fickett   Chief Financial Officer
    (Principal Financial and Accounting Officer)
      April 13, 2026
    Jaime Fickett    
           
    /s/ Alfred Baumeler   President and Director     April 13, 2026
    Alfred Baumeler    
             
    /s/ J. Paul SoRelle   Director   April 13, 2026
    J. Paul SoRelle    
           
    /s/ Nitin Kaushal   Director   April 13, 2026
    Nitin Kaushal    
           
    /s/ Teresa Thompson   Director   April 13, 2026
    Teresa Thompson    

     

    II-5

     

    Get the next $SNYR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNYR

    DatePrice TargetRatingAnalyst
    2/2/2026$5.00Buy
    Ascendiant Capital Markets
    1/21/2025$10.00Buy
    ROTH MKM
    More analyst ratings

    $SNYR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman Ross Jack bought $79,578 worth of shares (27,900 units at $2.85), increasing direct ownership by 7% to 410,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    7/31/25 8:31:46 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $29,837 worth of shares (16,100 units at $1.85), increasing direct ownership by 4% to 382,607 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    6/11/25 7:17:28 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $10,870 worth of shares (5,300 units at $2.05), increasing direct ownership by 1% to 366,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    5/21/25 5:05:31 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital Markets initiated coverage on Synergy CHC Corp. with a new price target

    Ascendiant Capital Markets initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $5.00

    2/2/26 6:52:55 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    ROTH MKM initiated coverage on Synergy CHC Corp. with a new price target

    ROTH MKM initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $10.00

    1/21/25 9:10:17 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Synergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

    NORTH WINDHAM, Maine, April 01, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three and twelve months ended December 31, 2025. "Our full year results reflect a year of meaningful strategic progress and continued advancement of our priority growth initiatives," said Jack Ross, CEO of Synergy CHC Corp. "During 2026 on the beverage side, we have shipped our Focus and Energy RTDs and shots into several new key distribution partners, including EG America, Wakefern Food, and Pine State Beverage, to name a few. With millions of cans of RTDs and shots in stock and ready to

    4/1/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference Call

    WESTBROOK, Maine, March 30, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced an updated date for the release of its fourth quarter and full year financial results ended December 31, 2025. The Company will now report its financial results on Wednesday, April 1, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be avail

    3/30/26 5:14:41 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Fourth Quarter and Full Year 2025 Earnings and Conference Call Information

    WESTBROOK, Maine, March 17, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's websi

    3/17/26 4:05:00 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    SEC Filings

    View All

    SEC Form S-8 filed by Synergy CHC Corp.

    S-8 - Synergy CHC Corp. (0001562733) (Filer)

    4/13/26 5:03:31 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 10-K filed by Synergy CHC Corp.

    10-K - Synergy CHC Corp. (0001562733) (Filer)

    3/31/26 9:23:47 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form NT 10-K filed by Synergy CHC Corp.

    NT 10-K - Synergy CHC Corp. (0001562733) (Filer)

    3/31/26 8:39:27 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Thompson Teresa Brigid

    3 - Synergy CHC Corp. (0001562733) (Issuer)

    10/2/25 9:47:13 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by President Baumeler Alfred

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    9/22/25 9:31:24 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Chief Financial Officer Fickett Jaime

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    9/22/25 9:26:09 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Financials

    Live finance-specific insights

    View All

    Synergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

    NORTH WINDHAM, Maine, April 01, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three and twelve months ended December 31, 2025. "Our full year results reflect a year of meaningful strategic progress and continued advancement of our priority growth initiatives," said Jack Ross, CEO of Synergy CHC Corp. "During 2026 on the beverage side, we have shipped our Focus and Energy RTDs and shots into several new key distribution partners, including EG America, Wakefern Food, and Pine State Beverage, to name a few. With millions of cans of RTDs and shots in stock and ready to

    4/1/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference Call

    WESTBROOK, Maine, March 30, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced an updated date for the release of its fourth quarter and full year financial results ended December 31, 2025. The Company will now report its financial results on Wednesday, April 1, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be avail

    3/30/26 5:14:41 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Fourth Quarter and Full Year 2025 Earnings and Conference Call Information

    WESTBROOK, Maine, March 17, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's websi

    3/17/26 4:05:00 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Leadership Updates

    Live Leadership Updates

    View All

    Synergy CHC Corp. (NASDAQ: SNYR) Appoints Pedro Colmenares as Director of Sales & Marketing for Mexico & Latin America

    WESTBROOK, Maine, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that Pedro Colmenares has been appointed Director of Sales & Marketing for Mexico & Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Mr. Colmenares joins the Company at a pivotal time as it advances its international growth strategy. As announced in May 2025, Synergy established a wholly owned subsidiary in Mexico and has begun its initial market entry through shipments of its supplement products to Costco Mexico this week. A

    12/16/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Lead Strategic Partnerships; Appoints Veteran Costco Buyer to Board of Directors

    Board member Scott Woodburn transitions to Head of Strategic Partnerships to accelerate FOCUSfactor Energy Drink expansion Former Costco Buyer Teresa Thompson brings nearly 40 years of retail expertise in vitamins and supplements WESTBROOK, Maine, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced two key leadership changes: Scott Woodburn has been appointed to Head of Strategic Partnerships to drive the Company's expansion in functional beverages, and Teresa Thompson has been appointed to Synergy's Board of Directors (the "Board"), effective immediately. In connection with Woodb

    9/22/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global Expansion

    WESTBROOK, Maine, June 10, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a fast-growing consumer health and wellness company, announced today that Damian Marano has been named Vice President of Beverage, effective immediately. This appointment marks a major milestone in the Company's aggressive push into the booming functional beverage market. "We're excited to welcome Damian to Synergy's executive leadership team," said Jack Ross, CEO of Synergy CHC Corp. "Damian's deep expertise in beverage, CPG, and technology-enabled growth adds another high-caliber industry veteran to further guide our beverage business through its next phase. His proven track

    6/10/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Synergy CHC Corp.

    SC 13D - Synergy CHC Corp. (0001562733) (Subject)

    10/31/24 9:55:58 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Synergy CHC Corp.

    SC 13G - Synergy CHC Corp. (0001562733) (Subject)

    10/25/24 7:46:44 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care